Hospital

This drug class works by interfering with the ability of cancer cells to repair themselves after experiencing damage to their DNA, but how PARP inhibitors selectively kill cancer cells was previously unknown.

The results of a study show that with proper antibiotic treatments and therapy, clinical outcomes for those with community-acquired pneumonia do not differ.

Study results show that these personalized treatments adjust based on cerebral function through electric pulses.

From an economic perspective, C. difficile has a staggering financial impact on the US health care system, as well on the patients infected.

Diabetic kidney disease develops in nearly 40% of patients with diabetes and serves as the leading cause of chronic kidney disease worldwide, according to the study.

As specialty drugs move through clinical trials and preparations for commercialization begin, significant attention is warranted to this process considering the massive investments that would have been already made in the product up to this point.

Harry Webster, RPh, a registered pharmacist at Walgreens and a member of the LGBTQIA+ community, discusses the impact of stigma associated with PrEP and HIV on patients seeking to treat or prevent HIV.

Michael Ganio, PharmD, MS, BCPS, FASHP, Senior Director of Pharmacy Practice and Quality at the American Society of Health-System Pharmacists, discussed the recent strains for hospitals due to the newest wave of COVID-19.

New evidence shows that moving to urban areas in the Midwest or either coast could increase the longevity of an individual’s life.

Research shows that individuals who had either a severe or mild case of the virus had an increased risk of kidney damage and disease.

Study shows the benefit of green and blue spaces for individuals with COPD living in urban communities.

As pharmacists were pulled into patient-facing roles, many hospitals were forced to scale back or make adjustments in medication compounding practices.

The guidance noted it is preferable for immunocompromised patients to receive their third dose in a health care delivery setting rather than a pharmacy or public vaccination clinic.

COVID-19 convalescent plasma administered within the first week of symptoms did not prevent disease progression in a high-risk group of outpatients.

Kidney disease is among the most common causes of both hyperkalemia and hypokalemia.

Following a phase 2 study, Moderna submitted initial data to the FDA for the approval of its COVID-19 booster shot that would be administered 6 months after an individual’s second dose.

Calls to poison control centers regarding the use of ivermectin for the prevention or treatment of COVID-19 have increased 5-fold since its baseline before the COVID-19 pandemic.

A study found individuals receiving probiotics had a decrease in C. difficile diagnosed in stool samples than those who did not receive probiotics.

Vaccinations are a huge success story in global health care and have helped eliminate smallpox and nearly eradicate polio.

The FDA has approved a second drug, zanubritinib, for the treatment of adult patients with Waldenström’s macroglobulinemia.

The study authors note that they cannot conclude that there is a causal relationship between the COVID-19 vaccines and any of the individual incidents of Bell palsy reviewed.

AZD7442 reduced the risk of developing symptomatic COVID-19 by 77% compared to placebo.

Lab values for sodium, potassium, chloride, magnesium, BUN, creatinine, glucose, and CO2.

Individuals with COVID-19 were more likely to be asymptomatic if they contracted the virus from a primary case that was also asymptomatic.

Atezolizumab was granted accelerated approval for the mTNBC indication in March 2019, making it the first immunotherapy agent to be approved in this setting.

The FDA's green light for the Alzheimer medication is worrisome, as clinical trials proved inconclusive.

Collaborative efforts between patients, physicians, pharmacists, and other essential personnel can further promote the effectiveness of PrEP regimens.

Further, their status was evaluated at 14, 21, and 28 days after treatment, and at each point, the numbers of hospitalization were significantly lower in the treated group.

The investigators, from Washington University School of Medicine in St. Louis, note that the responses measured were one-third as strong as those mounted by healthy individuals.

The FDA has also converted the indication for pembrolizumab from an accelerated to a full, regular approval for patients with urothelial carcinoma.